Galapagos receives transparency notification
Galapagos received a transparency notification on 2 March 2012 from Abingworth Management Limited, who acts as manager of Abingworth Bioventures III A LP, Abingworth Bioventures III B LP, Abingworth Bioventures III C LP, and Abingworth Bioventures III Executives LP and exercises voting rights for shares owned by those funds.
Galapagos has initiated a second phase I clinical trial for GLPG0259, a novel candidate drug being developed for rheumatoid arthritis.